Related Experiment Video

Updated: Dec 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Eric Powers1, Georgia Sofia Karachaliou2,3, Chester Kao1

  • 1Department of Medicine, Duke University, Durham, NC, 27710, USA.

Journal of Hematology & Oncology
|October 29, 2020
PubMed

Insights

New treatments for metastatic castration-resistant prostate cancer (mCRPC) include PARP inhibitors and radioligand therapy. These advancements offer personalized options for advanced prostate cancer patients, improving outcomes.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents a significant therapeutic challenge with limited effective treatments.
  • Current treatment options for mCRPC have shown limited efficacy in improving patient survival and disease course.

Purpose of the Study:

  • To review recent advancements in systemic therapies for mCRPC.
  • To highlight promising agents currently under clinical investigation for prostate cancer treatment.

Main Methods:

  • Literature review of recent clinical trials and therapeutic developments in mCRPC.
  • Focus on novel agents including poly ADP-ribose polymerase (PARP) inhibitors and radioligand therapy.

Main Results:

  • Poly ADP-ribose polymerase (PARP) inhibitors have emerged as a successful therapeutic strategy for mCRPC patients with DNA damage repair gene mutations.
  • 177-lutetium-prostate-specific membrane antigen (PSMA)-617, a radiotherapeutic agent, shows promise for PSMA-expressing prostate cancer.
  • Combinations of immunotherapy with existing treatments are also under investigation.

Conclusions:

  • Significant progress has been made in developing targeted and personalized systemic treatments for mCRPC.
  • Emerging therapies like PARP inhibitors and PSMA-targeted radioligand therapy represent promising avenues for improving outcomes in advanced prostate cancer.
Keywords:
Androgen receptor inhibitors (ARIs)Castration-resistant prostate cancerMetastatic prostate cancerPolyadenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitorProstate-specific membrane antigen (PSMA)

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

401
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
782